INTERVIEW: Sanford-Burnham leaders make the case for pharma partnerships
This article was originally published in Scrip
Michael Jackson, vice president of drug discovery and development at San Diego's Sanford-Burnham Medical Research Institute, brings big pharma experience to a nonprofit organization that isn't waiting for the industry to turn research into new medicines.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.